You are here: Industry Insights > T2D

News List

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials drugs
August 25, 2021
Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 25% of the planned 450 patients for its Phase 3 ORA-D-013-2 trial of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).
Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients pharmatimes
July 15, 2021
Bayer’s first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) Kerendia has received approval in the US to slow chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D).
Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes expresspharma
July 12, 2021
Bayer announced the United States (US) Food and Drug Administration (FDA) has approved KERENDIA (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline ...
COVID-19 to have long-term impact on global diabetes market: GlobalData expresspharma
May 24, 2021
As diabetes case numbers are expected to be further fuelled by COVID-19, and as the pathophysiology of COVID-19 induced diabetes is further explored, there will be more patients in need of targeted therapeutics.
Global diabetes therapeutic market has grown sixfold in last two decades: GlobalData expresspharma
May 20, 2021
The market has been a lucrative space for drug developers, as the disease is highly prevalent and patient numbers are expected to continue increasing in the foreseeable future.
Oramed Initiates Second Phase 3 Oral Insulin Study americanpharmaceuticalreview
March 30, 2021
Oramed Pharmaceuticals has screened the first patients in its ORA-D-013-2 study, the second of two concurrent Phase 3 studies of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Metavention Initiates Trial for Novel Treatment of Type 2 Diabetes americanpharmaceuticalreview
February 20, 2021
Metavention announced the initiation of an U.S. Food and Drug Administration (FDA) approved clinical investigation, DeLIVER, for the Company's intravascular iRF Denervation System to determine safety in patients with type 2 diabetes (T2D).
Bayer announces FDA accepts NDA and grants priority review for Finerenone for patients with CKD and T2D pharmaceutical-business-review
January 18, 2021
Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted Priority Review for finerenone, an investigational drug for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Farxiga Granted Priority Review in US for Chronic Kidney Disease americanpharmaceuticalreview
January 14, 2021
AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
US priority review for Forxiga in chronic kidney disease pharmatimes
January 07, 2021
The US Food and Drug Administration (FDA) has granted AstraZeneca’s Forxiga (dapagliflozin) a priority review for the treatment of new or worsening chronic kidney disease (CKD).

Previous page 1 2 Next page